Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

ITI with a VWF-Stabilised FVIII Concentrate in Haemophilia A Patients with Inhibitors and a Poor Prognosis for ITI Success: Progress Report on octanate ® in the Observational ObsITI Study,

Carmen Escuriola-Ettingshausen, MD, Vladimir Vdovin, MD, Nadezhda Zozulya, MD, PhD, Olga Plyushch, Prof, Wolfhart Kreuz, MD, Bruce A. Schwartz, PhD

Blood (2011) 118 (21): 3310.

https://doi.org/10.1182/blood.V118.21.3310.3310

Published: 2011

Journal Articles

Epitope Mapping of FIX Inhibitors Identify Contact Residues in the Protease Domain.

Sebastian Hoehl, Wolfhart Kreuz, MD, Nicole Krause, Diana Stichel, Inmaculada Martinez-Saguer, Christoph Kessel, Thomas Klingebiel, MD, Johannes Oldenburg, MD, PhD, James Irving, Christoph Königs

Blood (2009) 114 (22): 3172.

https://doi.org/10.1182/blood.V114.22.3172.3172

Published: 2009

Journal Articles

Rate of Inhibitor Development in Hemophilia A Patients Treated with Plasma Derived or Recombinant Factor VIII Concentrates. A Systematic Review of the Literature.

Alfonso Iorio, MD, Susan Halimeh, MD, Christoph Bidlingmaier, MD, Leonardo R. Brandao, MD, Carmen Escuriola-Ettingshausen, MD, Neil A Goldenberg, MD, PhD, Alessandro Gringeri, MD, MSc, Susanne Holzhauer, MD, Gili Kenet, MD, PhD, Ralf Knoefler, MD, Wolfhart Kreuz, MD, Karin Kurnik, MD, Daniela Manner, MD, Emanuela Marchesini, MD, Maura Marcucci, MD, Elena Santagostino, MD, PhD, Guy Young, MD, Pier Mannuccio Mannucci, MD, Ulrike Nowak-Gottl, MD

Blood (2009) 114 (22): 3154.

https://doi.org/10.1182/blood.V114.22.3154.3154

Published: 2009

Journal Articles

Peptide Multimers for Binding of Factor VIII Inhibitors.

Christoph Kessel, Wolfhart Kreuz, Katharina Klich, Frank Vorpahl, Karin Becker-Peters, Ursula Dietrich, Thomas Klingebiel, Christoph Königs

Blood (2008) 112 (11): 1224.

https://doi.org/10.1182/blood.V112.11.1224.1224

Published: 2008

Journal Articles

Effects of “Primary Prophylaxis” and “On-Demand” Therapy on the Clinical Expression of Severe Hemophilia A in Children - Results of a Multicenter Study.

Rosemarie Schobess, Karin Kurnik, Wolfhart Kreuz, Frauke Friedrichs, Anne Krumpel, Christoph Bidlingmaier, Carmen Escuriola Ettingshausen, Ulrike Nowak-Gottl

Blood (2007) 110 (11): 3146.

https://doi.org/10.1182/blood.V110.11.3146.3146

Published: 2007

Journal Articles

Inhibitor Epitopes Identified from Inhibitor Positive Plasma of a Hemophilia B Patient Change during ITT.

Christoph Königs, Christoph Kessel, Susanne Stumpf, Janti Roland, Thomas Klingebiel, Wolfhart Kreuz

Blood (2005) 106 (11): 3201.

https://doi.org/10.1182/blood.V106.11.3201.3201

Published: 2005

Journal Articles

Epitope Mapping of Inhibitors in Acquired Hemophilia by Phage Display.

Christoph Königs, Christoph Kessel, Sabine Scholz, Susanne Stumpf, Manuela Krause, Thomas Klingebiel, Wolfhart Kreuz

Blood (2005) 106 (11): 3202.

https://doi.org/10.1182/blood.V106.11.3202.3202

Published: 2005

Journal Articles

Ligand Mediated Targeting of FVIII Inhibitor Specific Primary B Cells Via Surface Immunoglobulin.

Christoph Kessel, Wolfhart Kreuz, Katharina Brassat, Thomas Klingebiel, Christoph Königs

Blood (2005) 106 (11): 3206.

https://doi.org/10.1182/blood.V106.11.3206.3206

Published: 2005

Journal Articles

Immune Tolerance Induction (ITI) in Hemophilia A and Inhibitors using VWF Containing Factor VIII Concentrates.

Wolfhart Kreuz, MD, Carmen Escuriola Ettingshausen, MD, Guenter K.H. Auerswald, MD, Hans Herrmann Brackmann, MD, Thomas Klingebiel, MD

Blood (2004) 104 (11): 3092.

https://doi.org/10.1182/blood.V104.11.3092.3092

Published: 2004

Journal Articles

Monitoring of FVIII Replacement Therapy with Cell-Based Monitoring Tests.

Steffen Bassus, MD, PhD, Wolfgang Wegert, MS, Manuela Krause, MD, Inge Scharrer, MD, Thomas Scholz, Eng., Carmen Escuriola-Ettinghausen, MD, Annelie Siegemund, MD, Wolfhart Kreuz, MD, Lothar Engelmann, MD, Carl M. Kirchmaier, MD

Blood (2004) 104 (11): 3098.

https://doi.org/10.1182/blood.V104.11.3098.3098

Published: 2004

Journal Articles

Epitope Mapping during FVIII Inhibitor Elimination with Rituximab Revealed Conformational Epitopes on FVIII and Identifies Potentially Small Molecules for Novel Therapies.

Christoph Königs, BSc(Hons), Christoph Kessel, Dipl Biol, Richard Linde, Thomas Klingebiel, Wolfhart Kreuz, PD

Blood (2004) 104 (11): 3081.

https://doi.org/10.1182/blood.V104.11.3081.3081

Published: 2004

Journal Articles

The Role of Age at First Exposure and Therapy Regimen on the Development of Neutralizing FVIII Antibodies in Hemophilia A.

Carmen Escuriola Ettingshausen, MD, Alexandra Zyschka, Inmaculada Martinez Saguer, MD, Christine Heller, MD, Thomas Klingebiel, MD, Wolfhart Kreuz, MD

Blood (2004) 104 (11): 3082.

https://doi.org/10.1182/blood.V104.11.3082.3082

Published: 2004

Journal Articles

Individual Replacement Therapy (IRT) with a Pasteurized C1-Inhibitor Concentrate Compared to Prophylaxis with Danazol in Patients with Hereditary Angioedema (HAE) - a Prospective Study.

Wolfhart Kreuz, MD, Inmarculada Martinez-Saguer, MD, Emel Aygoeren-Puersuen, MD, Eva Rusicke, MD, Thomas Klingebiel, MD

Blood (2004) 104 (11): 1028.

https://doi.org/10.1182/blood.V104.11.1028.1028

Published: 2004

Journal Articles

Pharmacokinetics of C1 Esterase Inhibitor, Human (Pasteurized) in Subjects with Hereditary Angioedema.

Wolfhart Kreuz, MD, Inmarculada Martinez-Saguer, MD, Hildegard Stoll, MD, Sigurd Knaub, PhD, Thomas Klingebiel, MD

Blood (2004) 104 (11): 1031.

https://doi.org/10.1182/blood.V104.11.1031.1031

Published: 2004

Journal Articles

Inhibitor Incidence in Previously Untreated Patients (PUP) with Hemophilia A and B - a 10-Year-Follow up of the Prospective Multicenter Study.

Wolfhart Kreuz, MD, Guenter K.H. Auerswald, MD, Ulrich Budde, MD, Harald Lenk, MD

Blood (2004) 104 (11): 3983.

https://doi.org/10.1182/blood.V104.11.3983.3983

Published: 2004

Journal Articles

Subcutaneous Immunoglobulin Substitutions in Previously Untreated (PUPs) and Treated Patients (PTPs) Result in Rapid Improvement of Total and Serum IgG Levels - a Novel Substitution Protocol for PUPs.

Christoph Königs, Dominik Dunsch, Richard Linde, Thomas Klingebiel, Prof, Dr, Wolfhart Kreuz, PD

Blood (2004) 104 (11): 3832.

https://doi.org/10.1182/blood.V104.11.3832.3832

Published: 2004

Journal Articles

Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors

Ulrike Nowak-Göttl, Ralf Junker, Wolfhart Kreuz, Arnold von Eckardstein, Andrea Kosch, Natascha Nohe, Rosemarie Schobess, Silke Ehrenforth

Blood (2001) 97 (4): 858–862.

https://doi.org/10.1182/blood.V97.4.858

Published: 2001

NARROW

ITI with a VWF-Stabilised FVIII Concentrate in Haemophilia A Patients with Inhibitors and a Poor Prognosis for ITI Success: Progress Report on octanate ® in the Observational ObsITI Study,

Epitope Mapping of FIX Inhibitors Identify Contact Residues in the Protease Domain.

Rate of Inhibitor Development in Hemophilia A Patients Treated with Plasma Derived or Recombinant Factor VIII Concentrates. A Systematic Review of the Literature.

Peptide Multimers for Binding of Factor VIII Inhibitors.

Effects of “Primary Prophylaxis” and “On-Demand” Therapy on the Clinical Expression of Severe Hemophilia A in Children - Results of a Multicenter Study.

Inhibitor Epitopes Identified from Inhibitor Positive Plasma of a Hemophilia B Patient Change during ITT.

Epitope Mapping of Inhibitors in Acquired Hemophilia by Phage Display.

Ligand Mediated Targeting of FVIII Inhibitor Specific Primary B Cells Via Surface Immunoglobulin.

Immune Tolerance Induction (ITI) in Hemophilia A and Inhibitors using VWF Containing Factor VIII Concentrates.

Monitoring of FVIII Replacement Therapy with Cell-Based Monitoring Tests.

Epitope Mapping during FVIII Inhibitor Elimination with Rituximab Revealed Conformational Epitopes on FVIII and Identifies Potentially Small Molecules for Novel Therapies.

The Role of Age at First Exposure and Therapy Regimen on the Development of Neutralizing FVIII Antibodies in Hemophilia A.

Individual Replacement Therapy (IRT) with a Pasteurized C1-Inhibitor Concentrate Compared to Prophylaxis with Danazol in Patients with Hereditary Angioedema (HAE) - a Prospective Study.

Pharmacokinetics of C1 Esterase Inhibitor, Human (Pasteurized) in Subjects with Hereditary Angioedema.

Inhibitor Incidence in Previously Untreated Patients (PUP) with Hemophilia A and B - a 10-Year-Follow up of the Prospective Multicenter Study.

Subcutaneous Immunoglobulin Substitutions in Previously Untreated (PUPs) and Treated Patients (PTPs) Result in Rapid Improvement of Total and Serum IgG Levels - a Novel Substitution Protocol for PUPs.

Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only